What I like about it...
- Price has cleared a significant Volume by Price
 
- Volume is constructive over the last 10 days...but more volume needs to come in to push it forward
 
- It is solvent (but not profitable) and has already had a recent public offering.
 
- Revenues are growing
 
- It's a biotech and subject to the vagaries of all biotechs.
 - It is not profitable, so there is a cash burn.
 
